A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Simple Search

You could also try: resembling (46)

InP (RICE) Carboplatin Etoposide Ifosfamide Rituximab

Description
Chemotherapy Protocol LYMPHOMA CARBOPLATIN-ETOPOSIDE-IFOSFAMIDE-RITUXIMAB (RICE) Inpatient Regimen Regimen • Lymphoma – InP-RICE-Carboplatin-Etoposide-Ifosfamide-Rituximab Indication • Non Hodgkin
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-RICE-Carboplatin-Etoposide-Ifosfamide-Rituximab.pdf

AmB Carboplatin Etoposide Ifosfamide Rituximab (RICE)

Description
Chemotherapy Protocol LYMPHOMA CARBOPLATIN-ETOPOSIDE-IFOSFAMIDE-RITUXIMAB (RICE) Ambulatory Regimen Regimen • Lymphoma – AmB-RICE-Carboplatin-Etoposide-Ifosfamide-Rituximab Indication • Non Hodgkin
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/AmB-Carboplatin-Etoposide-Ifosfamide-Rituximab-RICE-Ver1.1.pdf

Carboplatin and Vinorelbine (intravenous)

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CARBOPLATIN-VINORELBINE (Intravenous) Regimen • NSCLC – Carboplatin-Vinorelbine (intravenous) Indication • First line therapy of
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/CarboplatinandVinorelbineintravenous.pdf

Papers-CoG 26.04.2023

Description
Agenda attachments 1 CoG Agenda - 26.04.2023.docx Date Time Location Chair Agenda Council of Governors 26/04/2023 14
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Governors/Papers-CoG-26.04.2023.pdf

Cyclophosphamide-Prednisolone-Rituximab- R-CP (21)

Description
Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-PREDNISOLONE-RITUXIMAB (R-CP) Regimen • Lymphoma – R-CP (21)-Cyclophosphamide-Prednisolone-Rituximab Indication • Lymphoplasmacytic lymphoma/Waldenstrom’s
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Cyclophosphamide-Prednisolone-Rituximab-R-CP-21.pdf

BRC NMAHP researcher initiation internship award checklist 2023

Description
Name: Proposed Project Title: Contact details: Criteria Email: Mobile: 1. Registration with an appropriate UK regulatory and professional body: Evidence submitted
Url
/Media/Southampton-Clinical-Research/Downloads/BRC-NMAHP-researcher-initiation-internship-award-checklist-2023.pdf

InP-LEAM

Description
Chemotherapy Protocol LYMPHOMA LOMUSTINE-CYTARABINE-ETOPOSIDE (split)-MELPHALAN (LEAM) Inpatient Regimen Regimen Lymphoma – InP-LEAM (split)-Lomustine-Cytarabine-Etoposide-Melphalan Indication
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-LEAM.pdf

mini-RCHOP 21

Description
Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-DOXORUBICIN-PREDNISOLONE-RITUXIMAB-VINCRISTINE (mini-RCHOP 21) Regimen   Lymphoma – mini-RCHOP (21)-Cyclophosphamide-Doxorubicin-PrednisoloneRituximab-Vincristine Indication
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/mini-RCHOP-21.pdf

Atezolizumab-Bevacizumab

Description
Chemotherapy Protocol Hepatocellular Cancer ATEZOLIZUMAB-BEVACIZUMAB Regimen  HCC-Atezolizumab-Bevacizumab Indication  Atezolizumab in combination with bevacizumab for the first-line systemic
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Hepatobiliary/Atezolizumab-Bevacizumab.pdf

MyelomaBortezomib IV DexamethasonePabinostatThalidomide 21day Ver1.1

Description
Chemotherapy Protocol MULTIPLE MYELOMA BORTEZOMIB (IV)-DEXAMETHASONE-PANOBINOSTAT-THALIDOMIDE Regimen (21 day) • Multiple Myeloma – Bortezomib (IV)-Dexamethasone-Panobinostat-Thalidomide (21 day
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaBortezomib-IV-DexamethasonePabinostatThalidomide-21day-Ver1.1.pdf
151 to 160 of 757
Previous … 14 15 16 17 18 … Next